Genetic pharmacology of platinum-based combination chemotherapy for non-small cell lung cancer

Genetic pharmacology of platinum-based combination chemotherapy for non-small cell lung cancer

June 10, 2015 Source: Bio Valley

Yin Jiye, MD, associate professor, postgraduate tutor, director of the Laboratory of Cellular and Molecular Biology, Institute of Clinical Pharmacology, Central South University, deputy director of the Molecular Genetics and Pharmacology Laboratory, and Deputy Director of Technology, Xiangya Medical Laboratory.

Director Yin gave a speech on the pharmacogenetic study of platinum-based combination chemotherapy for non-small cell lung cancer at the 2014 Tumor Transition Medicine Symposium. The video has been uploaded to Xunyun College for exchange learning.

Lung cancer is a common tumor that harms human life and health in China and around the world. So far, platinum-based chemotherapy is still the main treatment for non-small cell lung cancer, especially for advanced tumors.

However, in clinical practice, there are huge differences in the efficacy of chemotherapy in different patients. With the deepening of pharmacogenetics research, more and more evidence supports the influence of gene mutation on the sensitivity of platinum-based chemotherapy combined with chemotherapy in non-small cell lung cancer. Therefore, understanding the relationship between genetic variation and platinum drug chemosensitivity is helpful to establish an individualized treatment system for lung cancer patients.

However, there is currently no genetic variation that can be used to accurately predict the chemosensitivity of platinum drugs. Therefore, Director Yin and his team analyzed 31 key genes in the platinum drug pathway (ATP7A, ATP7B, AQP2, AQP9, MVP, OCT2, TMEM205, SLC2A1, SIRT1, HSPB1, HSPE1, HSPA4, RAC1, RhoA, HMGB1, HMGB2, Relationship between 214 polymorphisms of SSRP1, MLH1, MSH2, MSH3, MSH4, MSH5, MSH6, ABCG2, XPA, ERCC5, SRCC1, GSTT1, WISP1, eIF3a, VCP) and platinum-based chemosensitivity in non-small cell lung cancer OCT2 (rs195854, rs195854), TMEM205 (rs896412), AQP9 (rs1516400), AQP2 (rs7314734), ATP7B (rs9535828, rs9535826), eIF3a (rs3740556) were significantly associated with platinum-based chemotherapy.

To identify new genetic mutations associated with platinum-based chemotherapy susceptibility to non-small cell lung cancer, 17 patients with significant resistance and sensitivity to platinum-based chemotherapy were selected for full exome sequencing studies. The rs2280497 and rs2293106 of adenylate cyclase 1 were found to be associated with platinum-based chemotherapy sensitivity in non-small cell lung cancer, and were initially validated in a small sample population.

Watch the speech video → http://xy.bioon.com/course_video/yin-ji-ye-fei-xiao-xi-bao-fei-ai-bo264932.html

Thickening Agent

We provide a variety of natural Food Additive thickeners, including Xanthan gum, AGAR powder, gellan gum, Corderan gum, gelatin, guar gum, Acacia gum, konjac gum, carrageenan, pectin, sodium alginate, methyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, etc.

Thickening Agent,Natural Thicking Agent,Food Grade Thicking Agent,Water Based Thickening Agent

Allied Extracts Solutions , https://www.alliedbiosolutions.com